ClinicalTrials.gg
CompletedNCT02004587Updated Jul 14, 2014

Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD After Multiple Oral Doses in Healthy White Volunteers

A Phase 1 interventional study of Gemigliptin in Hepatic Impairment, sponsored by LG Life Sciences. Completed at 1 site in Germany. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-14.

Sponsored by LG Life Sciences (part of LG Chem) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The trial will investigate the influence of hepatic function on the PK of gemigliptin. In an additional treatment period, the PK and safety of multiple dosing of gemigliptin in healthy White subjects will be investigated.

02

Conditions studied

  • Hepatic Impairment

Keywords

  • Hepatic impairment
  • Pharmacokinetics
  • Pharmacodynamics
  • Gemigliptin
03

In context

Lead sponsor

LG Life Sciences is the lead sponsor of 78 studies on the registry; none are open to participants now.

First submitted before LG Life Sciences became part of LG Chem.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects who are able to understand and follow instructions during the study and available for study participation.
  • Signed .
  • White

Exclusion criteria

Exclusion Criteria:

  • Unwilling or unable to give .
  • As a result of the medical screening process, a study physician considers the subject unfit for the study.
  • The subject has a history of drug or other allergy which study participation.
  • Female subjects who are pregnant or lactating.
  • Any other condition (surgical or medical) or history of severe disease with sequelae which increases the risk to the subject or affected absorption, distribution, metabolism or excretion of the study drug or otherwise
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    Mild hepatic impairment group

    Mild hepatic impairment group by Child-Pugh scores

    Drug: Gemigliptin

  • Experimental
    Moderate hepatic impairment group

    Moderate hepatic impairment group by Child-Pugh scores

    Drug: Gemigliptin

  • Active comparator
    Healthy volunteers

    Gemigliptin dosing in Healthy subjects

    Drug: Gemigliptin

Interventions

  • Gemigliptin is administered to each hepatic impairment subject for single oral dose. Also it is administered to healthy volunteer for single and multiple doses.

    Also known as: Zemiglo

06

What researchers measure

Primary outcomes

  1. AUC

    Blood samples will be prepared at planed points.

    Time frame: Several time points until 72hr

07

Study locations

1 site
  • CRS Clinical Research Services
    Kiel, Schleswig-Holstein 24105, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of May 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2013
First posted
Dec 9, 2013
Start
Sep 2013
Primary completionActual
May 2014
CompletionActual
Jul 2014
Last update
Jul 14, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02004587
Lead sponsor
LG Life Sciences
Responsible party
Sponsor
First posted
Dec 9, 2013
Start date
Sep 2013
Primary completion
May 2014
Completion
Jul 2014
Last update
Jul 14, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gemigliptin

Start the discussion